Biohaven secures up to $600M non-dilutive financing from Oberland Capital for troriluzole development

Biohaven Ltd.

First tranche $250M funded at closing on or before April 30, 2025.
Second tranche up to $150M available upon FDA approval of troriluzole; third tranche up to $200M for acquisitions.
Oberland receives tiered single-digit royalties on global troriluzole net sales for up to 10 years, capped at multiples.
Additional milestone payment of 35% of funded amount upon FDA or EMA approval.
Proceeds to support ongoing clinical trials and commercialization preparations for troriluzole in SCA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.